Abstract:Gene therapy is the most promising treatment for recessive dystrophic epidermolysis bullosa (RDEB), however genetic cargo delivery efficiency is still a technical limitation. Viruses are the traditional vector of preference for gene therapy, as virus trophism increase tissue specificity. However, drawbacks related with safety and high manufacturing costs have facilitated the expansion of non-viral vectors, such as liposomes and cationic polymers. Our group is focused on the development of highly branched cationic polymers for gene therapy to treat RDEB. Our polymers have demonstrated encapsulation and delivery of a full COL7A1 cDNA with no toxicity, performing better transfection efficiencies than commercial counterparts in RDEB keratinocytes. In this work, we show the research progress expanding the polymer technology for mRNA and ribonucleoprotein complex delivery for developing CRISPR/Cas9 based gene editing therapies for RDEB. Gene edition in vivo has been achieved by a single topical application, obtaining efficiencies comparable with viral vectors (Ad5). Endosomal escape, by peptide polymer decoration is being investigated to improve efficiency in vivo by avoiding endosomal retention. Storage of the nanoparticles, formed by polymers and the genetic cargo, at -20C ensures no reduction in efficiency for more than 6 months. However, in order to avoid cold chain challenges, nanoparticles have been lyophilised, increasing dose concentration and facilitating formulation with skin absorption enhancers for topical application. Proven ability to transfect stem cells combined with high efficiencies transfecting with multiple plasmids at the same time, should contribute to the success of prime editing strategies to pursue permanent correction of potential >89% of all described EB disease-associated mutations. The developed polymer platform shows high potential to be adapted to a wide range of genetic approaches for RDEB, including the most novel ones.

Exploring the potential of cell-derived vesicles for transient delivery of gene editing payloads

CRISPR delivery with extracellular vesicles: Promises and challenges

Gene Editing by Extracellular Vesicles

Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets

CRISPR/Cas9 delivery strategies with engineered extracellular vesicles

Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing

Gene editing by ferrying of CRISPR/Cas ribonucleoprotein complexes in enveloped virus-derived particles

Non-viral Delivery of CRISPR–Cas9 Complexes for Targeted Gene Editing Via a Polymer Delivery System

476 Non-viral Gene Delivery Platform for Topically Treating Rare Genodermatoses

The Future of Gene Therapy: A Review of In Vivo and Ex Vivo Delivery Methods for Genome Editing-Based Therapies

Small extracellular vesicles (sEVs)-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing

Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins

CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles

Non-viral systems for intracellular delivery of genome editing tools

Engineered Cas9 extracellular vesicles as a novel gene editing tool

Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for in Vivo CRISPR/Cas-Based Genome Editing.

Engineered materials for in vivo delivery of genome-editing machinery

Functionalized extracellular nanovesicles as advanced CRISPR delivery systems

Liposome-Based Carriers for CRISPR Genome Editing

Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing